Caprock Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11,078
| Closed | -$944K | – | 1159 |
|
|
2025
Q4 | $944K | Buy |
11,078
+4,964
| +81% | +$407K | 0.02% | 617 |
|
|
2025
Q3 | $497K | Buy |
+6,114
| New | +$478K | 0.01% | 807 |
|
|
2025
Q1 | $650K | Buy |
8,965
+554
| +7% | +$39.7K | 0.02% | 618 |
|
|
2024
Q4 | $623K | Buy |
+8,411
| New | +$589K | 0.02% | 551 |
|
|
2024
Q2 | – | Sell |
-6,640
| Closed | -$635K | – | 879 |
|
|
2024
Q1 | $635K | Buy |
6,640
+39
| +0.6% | +$3.28K | 0.04% | 351 |
|
|
2023
Q4 | $503K | Sell |
6,601
-2,010
| -23% | -$140K | 0.03% | 387 |
|
|
2023
Q3 | $597K | Buy |
8,611
+392
| +5% | +$31.5K | 0.05% | 325 |
|
|
2023
Q2 | $775K | Sell |
8,219
-572
| -7% | -$49.7K | 0.06% | 266 |
|
|
2023
Q1 | $727K | Buy |
+8,791
| New | +$691K | 0.06% | 264 |
|
|
2022
Q4 | – | Sell |
-9,621
| Closed | -$795K | – | 576 |
|
|
2022
Q3 | $795K | Buy |
+9,621
| New | +$926K | 0.08% | 186 |
|
|
2022
Q2 | – | Sell |
-10,607
| Closed | -$1.25M | – | 578 |
|
|
2022
Q1 | $1.25M | Buy |
+10,607
| New | +$1.19M | 0.12% | 136 |
|
|
2021
Q2 | – | Sell |
-9,375
| Closed | -$784K | – | 530 |
|
|
2021
Q1 | $784K | Sell |
9,375
-151
| -2% | -$12.8K | 0.09% | 174 |
|
|
2020
Q4 | $866K | Buy |
9,526
+1,085
| +13% | +$90K | 0.1% | 152 |
|
|
2020
Q3 | $674K | Sell |
8,441
-295
| -3% | -$23K | 0.09% | 166 |
|
|
2020
Q2 | $604K | Buy |
8,736
+2,379
| +37% | +$169K | 0.09% | 169 |
|
|
2020
Q1 | $400K | Buy |
6,357
+126
| +2% | +$9.09K | 0.08% | 186 |
|
|
2019
Q4 | $485K | Sell |
6,231
-60
| -1% | -$4.68K | 0.09% | 168 |
|
|
2019
Q3 | $461K | Sell |
6,291
-99
| -2% | -$6.95K | 0.09% | 166 |
|
|
2019
Q2 | $393K | Sell |
6,390
-870
| -12% | -$52.6K | 0.08% | 194 |
|
|
2019
Q1 | $463K | Buy |
7,260
+2,367
| +48% | +$135K | 0.09% | 189 |
|
|
2018
Q4 | $250K | Sell |
4,893
-3,126
| -39% | -$158K | 0.06% | 275 |
|
|
2018
Q3 | $465K | Sell |
8,019
-2,337
| -23% | -$114K | 0.09% | 176 |
|
|
2018
Q2 | $503K | Buy |
10,356
+576
| +6% | +$26.9K | 0.11% | 168 |
|
|
2018
Q1 | $455K | Hold |
9,780
| – | – | 0.1% | 200 |
|
|
2017
Q4 | $394K | Buy |
9,780
+825
| +9% | +$30.3K | 0.08% | 234 |
|
|
2017
Q3 | $326K | Buy |
8,955
+885
| +11% | +$33.8K | 0.07% | 265 |
|
|
2017
Q2 | $318K | Buy |
+8,070
| New | +$295K | 0.07% | 266 |
|
|
2017
Q1 | – | Sell |
-9,249
| Closed | -$289K | – | 360 |
|
|
2016
Q4 | $289K | Sell |
9,249
-519
| -5% | -$16.8K | 0.07% | 237 |
|
|
2016
Q3 | $393K | Buy |
+9,768
| New | +$368K | 0.09% | 215 |
|
Other funds holding EW
VCM
VPM
Caprock Group's EW Position: Q1 2026 in Review
Caprock Group sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 11,078 shares — an estimated $944K sold.
Caprock Group first reported a position in EW in Q3 2016 and held it in 29 quarters. The position peaked at $1.25M in Q1 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Caprock Group reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
- Caprock Group sold 11,078 Edwards Lifesciences shares in Q1 2026, an estimated $944K.
- Caprock Group first reported a position in Edwards Lifesciences in Q3 2016 and held it in 29 quarters.
- Caprock Group's Edwards Lifesciences position peaked at $1.25M in Q1 2022.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.